These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6854139)

  • 21. Biliary secretion of sulindac and metabolites in man.
    Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE
    Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.
    Kanfer I; Brown C; Konings M; Swarbrick J
    Biopharm Drug Dispos; 1996 Apr; 17(3):209-21. PubMed ID: 8983396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone.
    Kitamura S; Tatsumi K
    Jpn J Pharmacol; 1982 Oct; 32(5):833-8. PubMed ID: 7176218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medical use of dimethyl sulfoxide (DMSO).
    Swanson BN
    Rev Clin Basic Pharm; 1985; 5(1-2):1-33. PubMed ID: 3916302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enterohepatic circulation of sulindac and metabolites.
    Dujovne CA; Pitterman A; Vincek WC; Dobrinska MR; Davies RO; Duggan DE
    Clin Pharmacol Ther; 1983 Feb; 33(2):172-7. PubMed ID: 6822030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibuprofen and sulindac kinetics in alcoholic liver disease.
    Juhl RP; Van Thiel DH; Dittert LW; Albert KS; Smith RB
    Clin Pharmacol Ther; 1983 Jul; 34(1):104-9. PubMed ID: 6861431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism in vitro of sulindac. Sulfoxide-reducing enzyme systems in guinea pig liver.
    Kitamura S; Tatsumi K; Yoshimura H
    J Pharmacobiodyn; 1980 Jun; 3(6):290-8. PubMed ID: 6775073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal metabolism of sulindac, a novel nonsteroidal antiinflammatory agent.
    Miller MJ; Bednar MM; McGiff JC
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():487-91. PubMed ID: 6221568
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.
    Kapetanovic IM; Krishnaraj R; Martin-Jimenez T; Yuan L; van Breemen RB; Lyubimov A
    Chem Biol Interact; 2006 Dec; 164(1-2):68-75. PubMed ID: 17027946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism.
    Davis PJ; Guenthner LE
    Xenobiotica; 1985 Oct; 15(10):845-57. PubMed ID: 4072250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The reduction of sulphinpyrazone and sulindac by intestinal bacteria.
    Strong HA; Renwick AG; George CF; Liu YF; Hill MJ
    Xenobiotica; 1987 Jun; 17(6):685-96. PubMed ID: 3630204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A kinetic study of sulindac in the elderly.
    Bayley N; Warne RW; Moulds RF; Bury RW
    Aust N Z J Med; 1987 Feb; 17(1):39-42. PubMed ID: 3476045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
    Piazza GA; Rahm AK; Finn TS; Fryer BH; Li H; Stoumen AL; Pamukcu R; Ahnen DJ
    Cancer Res; 1997 Jun; 57(12):2452-9. PubMed ID: 9192825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: dimethyl sulfoxide inhibits IL-6-induced differentiation of SKW6-CL4 into IgM-secreting plasma cells.
    Teraoka H; Mikoshiba M; Takase K; Yamamoto K; Tsukada K
    Exp Cell Res; 1996 Jan; 222(1):218-24. PubMed ID: 8549666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individual variability in concentrations of urinary sulindac sulfide.
    Brandli DW; Sarkissian E; Ng SC; Paulus HE
    Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The disposition of sulindac.
    Duggan DE; Hare LE; Ditzler CA; Lei BW; Kwan KC
    Clin Pharmacol Ther; 1977 Mar; 21(3):326-35. PubMed ID: 300048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placental transfer of sulindac and its active sulfide metabolite in humans.
    Kramer WB; Saade G; Ou CN; Rognerud C; Dorman K; Mayes M; Moise KJ
    Am J Obstet Gynecol; 1995 Mar; 172(3):886-90. PubMed ID: 7892880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetics of sulindac in aged patients presenting with inflammatory joint disease].
    Mignot A; Lefebvre MA; Couet W; Dourthe C; Marechaud R; Fourtillan JB
    Therapie; 1989; 44(4):253-6. PubMed ID: 2595642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.